Kingsley Ndoh, Project Director, Clincial Assistant Professor at University of Washington, Founder and CEO at Hurone AI, shared a post by Hurone AI on LinkedIn, adding:
“When I founded Hurone AI, the goal was clear: ensure that a cancer patient anywhere including rural and underserved areas receives the exact same standard of care as someone sitting in the world’s leading academic medical centers.
It’s increasingly clear to me that building life-saving AI technology is only half the battle. True impact only happens when innovation integrates seamlessly into the operational, regulatory, and reimbursement realities of our healthcare system.
I am incredibly honored and humbled to welcome Dr. Lee Fleisher to the Hurone AI Board of Directors, to help us do just that.
As the former Chief Medical Officer at CMS (Centers for Medicare and Medicaid Services), Lee’s extensive experience in federal clinical standards, health policy, and scaled adoption is unparalleled. More importantly, he shares our deep commitment to closing the cancer care gap.
Lee, thank you for trusting our team and our vision. Your insights will be instrumental as we advance our platform across major U.S. health systems and build an AI infrastructure that providers and patients can trust, deploy, and sustain, at scale
Read more about our announcement here.”
Quoting Hurone AI post:
“We are proud to announce that national healthcare leader and former Centers for Medicare and Medicaid Services (CMS) Chief Medical Officer, Dr. Lee Fleisher, is joining the Hurone AI Board of Directors!
Dr. Fleisher’s background in defining national clinical standards and Medicare coverage pathways will be instrumental as we scale our AI-native oncology navigation infrastructure across the U.S.
Together, we are building a regulatory and clinical foundation that health systems can trust, ensuring that patients everywhere, including rural areas receive the highest standard of cancer care.
Welcome to the team, Dr. Fleisher!
Read the announcement.”
Other articles featuring Kingsley Ndoh and Lee Fleisher on OncoDaily.